84 results about "Rifamycin" patented technology

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

The invention features an ascending dose regimen for the administration of rifamycin-class antibiotics. The dosing regimen can be used to treat bacterial infections and diseases related to infection.

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

The invention provides a sterilizing method of a spherical phaeocystis culture solution, and relates to a microalgae culture solution. The method comprises the following steps: centrifuging algae solution which grows to an exponential phase, and removing supernatant; carrying out gravity suspension on algae cells with an f / 2 culture medium, centrifuging, and removing supernatant, repeating twice, and carrying out gravity suspension on the algae cells with the f / 2 culture medium; adding SDS (sodium dodecyl sulfate) and antibiotics, wherein the antibiotics are clindamycin, azithromycin, gentamicin, kanamycin, streptomycin, cefotaxime, ampicillin and rifamycin; culturing under illumination, centrifuging the algae solution and removing supernatant during culturing, carrying out gravity suspension on the algae cells with the f / 2 culture medium, centrifuging and removing supernatant, removing residual SDS and the antibiotics, transferring into the f / 2 culture medium, and culturing under illumination; and selecting survival transferred algae solution which is treated with SDS and the antibiotics, and detecting whether bacteria exist or not after the transferred algae solution grows to the exponential phase. The method is convenient to operate, complex operations, such as bacterium separation and test on sensitivity to antibiotics and the like, are avoided, and long-term treatment of high-concentration antibiotics has good sterilization effect.

A method for imparting broad spectrum antimicrobial activity to a medical device. The medical device is sequentially contacted with a first antimicrobial component, such as an antiseptic, and thereafter with a second antimicrobial component, such as a mixture of antibiotics. The first component may be a guanidium compound, such as chlorhexidine. The second component may be a mixture of a tetracycline, such as minocycline, and a rifamycin, such as rifampin.

The invention relates to a treating method for wastewater produced in production of rifamycin. The treating method comprises the following steps: (1) pretreating wastewater produced in production of rifamycin by using advanced oxidation technology; (2) subjecting oxidation effluent to coagulating sedimentation and carrying out filtering to remove sediments; (3) carrying out anaerobic biochemical treatment on effluent of filtering; and (4) subjecting anaerobic effluent to treatment via a biological contact oxidation process and adding salt-resistant COD-removing bacteria, wherein the salt-resistant COD-removing bacteria are Paracoccus sp. FSTB-2 and / or Pseudomonas stutzeri FSTB-5, and Paracoccus sp. FSTB-2 and Pseudomonas stutzeri FSTB-5 are preserved in China General Microbiological Culture Collection Center on June 1, 2015, with accession numbers of CGMCC NO. 10938 and CGMCC NO. 10940, respectively. According to the invention, the process of advanced oxidation, coagulating sedimentation, anaerobic biochemical treatment and biological contact oxidation is employed, and the specific salt-resistant COD-removing bacteria are added into a contact oxidation unit and can tolerate antibiotics in the wastewater, so high-efficiency stable removal of CODs in the wastewater is realized; and the treating method has the characteristics of simple process, high treating efficiency, low treating cost, etc.

The invention discloses an application of a rifamycin-nitroimidazole coupling molecule shown in formula I in restraining anaerobic flora. The rifamycin-nitroimidazole coupling molecule shown in formula I provided by the invention has a broad-spectrum antibacterial activity to anaerobion, has an activity to most pathogenic bacteria related to bacterial vaginosis, has a better in vitro antimicrobial activity than that of bacterial vaginosis drugs, such as, metronidazole and clindamycin, and has an excellent application prospect at the aspect of preventing and treating the bacterial vaginosis or the other related diseases caused by the anaerobion.

The invention discloses a preparation method of a rifamycin-nitroiminazole coupled molecule. By using metronidazole as the raw material and changing the synthesis route, the preparation method overcomes the defect that the reaction condition must be controlled at low temperature, and enhances the yield of the target product.

The present invention discloses a novel application of rifamycin-nitroimidazole coupling molecule and belongs to the field of medicinal chemistry. The rifamycin-nitroimidazole coupling molecule shows high activity to drug-resistant strains in the treatment of undistinguishable Clostridium, Helicobacter pylori infection related diseases, not only has antibacterial resistant activity to the rifamycin single drug-resistance bacteria and metronidazole single drug-resistance bacteria, but also has antibacterial activity against rifamycin resistant and metronidazole double drug-resistance bacteria; and the activity of the coupling molecule is superior to that of the composition of rifampicin and metronidazole in the molar ratio of 1:1.

Selective enrichment media and methods for selectively growing and detecting Salmonella spp. The media comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. The selective agents and efflux pump inhibitors are provided in the media in combinations and amounts that inhibit growth of non-Salmonella microorganisms without substantially affecting growth and metabolism of Salmonella species. Methods of selectively growing and detecting Salmonella species are provided.

The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and / or the treatment of bone and joint infections, especially for the prophylaxis and / or treatment of osteomyelitis.

The invention provides methods, compositions, and kits for treating a variety of bacterial infections, including prosthetic joint infections, infections caused by medical implants, infectious arthritis, and osteomyelitis. The methods, compositions, and kits employ rifamycins of any one of formulas (I)-(V).

The invention discloses streptomyces albidoflavus and application thereof in production of epsilon polylysine, and belongs to the field of microbial fermentation engineering. The Streptomyces albus GS114 provided by the invention can grow on an agar culture medium containing more than 10 [mu] g / ml of one or more of streptomycin, gentamycin and rifamycin, shows very strong antibiotic resistance, can normally grow in a liquid culture medium with a pH value of 2.5-3.0 and can synthesize a large amount of epsilon PL, and after fermentation for 200 h, the Streptomyces albus GS114 can be used as anantibiotic. The concentration of epsilon polylysine in the fermentation liquor is 65.7 g / L, and the yield of epsilon polylysine reaches 80.0 g / L or above after fermentation is conducted for 240 h. Thestrain also has good passage stability, and is an epsilon PL industrial production strain with great potential.

The present invention is directed to 13C and / or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and / or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and / or condition), especially an autophagy mediated disease state and / or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and / or conditions, especially of the lung. Methods of treating autophagy disease states and / or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.